Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer-Reviewed Technical Note: Quality by Design in Freeze-Drying
Cycle design and robustness testing using advanced process analytical technology.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 88-93


Figure 2
The "adjustment" of the profile showing T s over time (averaging of the SMART shelf-temperature settings during primary drying to obtain a constant shelf temperature over time) and P c setting (increase of P c from 52 to 62 mTorr) was conducted to further improve the recipe and to facilitate scale-up (see Figure 2) (10). T p and R p profiles over time for this modified cycle were found in very good agreement to the initial SMART cycle with a maximum temperature of –34.8 C during the run (see Figure 3 and Table I). Total primary drying time was 1190 min, or about 5% longer than the initial cycle recipe. It is important to note that the product processed in both cycles showed no indication of shrinkage or collapse (see Figure 5a).


Figure 3
Impact of T s and P c variation on product temperature. For 50 mg/mL sucrose, variation of shelf temperature of 5 C had very little influence on the profile of T p over time (see Figure 3). However, an increase in P c from 52 to 200 mTorr led to a significant increase in T p (>3 C), thereby exceeding T c . In contrast, an increase in solid content to 200 mg/mL and use of identical process conditions revealed only an increase of 1 C in T p .




Theoretical modeling of the freeze-drying cycle is an alternative method to gain a better understanding of the impact of process variables on the product-temperature profile. A one-dimensional steady state of the freeze-drying process was used to simulate the influence of T s and P c variations on T p for the 50 mg/mL sucrose solution. Note that T s and P c parameters were used according to the experimental design described above (see Figure 3 and Table I). During primary drying, the system is in a "pseudo steady state" and the following equation can be applied to predict product temperature (3, 11):


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here